PBM

PSYENCE BIOMEDICAL LTD. PBM

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-6.94M

Quarter to Mar 31

Free cash flow

$-8.14M

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$1.36M total
Parallel Advisors, LLC
$575.4K0.0%
AdvisorShares Investments LLC
$373.9KNew
MORGAN STANLEY
$115.7KNew
JANE STREET GROUP, LLC
$93.1KNew
XTX Topco Ltd
$46.2KNew
CITADEL ADVISORS LLC
$35.8KNew
Harraden Circle Investments, LLC
$27.9K-0.1%
Polar Asset Management Partners Inc.
$16.6K0.0%
MMCAP International Inc. SPC
$14.6K0.0%
TORONTO DOMINION BANK
$12.1K-0.1%
Calamos Advisors LLC
$10.5K0.0%
Saba Capital Management, L.P.
$7.2K0.0%
Clear Street Group Inc.
$6.3K0.0%
GOLDMAN SACHS GROUP INC
$4.9K0.0%
LMR Partners LLP
$4.9K0.0%
D. E. Shaw & Co., Inc.
$3.7K0.0%
TENOR CAPITAL MANAGEMENT Co., L.P.
$3.6K0.0%
WOLVERINE ASSET MANAGEMENT LLC
$3.6K0.0%
ARISTEIA CAPITAL, L.L.C.
$2.6K-46.4%
LPL Financial LLC
$1.2K0.0%
Mint Tower Capital Management B.V.
$1.0K0.0%
Stonehage Fleming Financial Services Holdings Ltd
$2720.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$212New
UBS Group AG
$184-75.7%
Ancora Advisors, LLC
$121New
See all 27 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2026
EDGAR

EPS (Diluted)

FY 2026
EDGAR

ROIC

FY 2026
EDGAR

Free Cash Flow

FY 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/PBM

Earnings Per Share

13fpro.ai/company/PBM

Loading ratio trend…

About PSYENCE BIOMEDICAL LTD. (PBM): stock profile, AI score and financials

PSYENCE BIOMEDICAL LTD. (PBM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. PBM is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2026), PSYENCE BIOMEDICAL LTD. reports net income of $-6.9M, free cash flow of $-8.1M. Top institutional holders of PBM by reported 13-F value include Parallel Advisors, AdvisorShares Investments, MORGAN STANLEY, based on the most recent SEC filings. PBM trades on the Nasdaq exchange and files with the SEC under CIK 1985062. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PBM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PSYENCE BIOMEDICAL LTD. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1985062 →